Plain-English translation of NCT07260942 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
Researchers are trying to understand how a process called ferroptosis — an iron-regulated type of cell death — contributes to lupus (SLE). The team has developed selenium compounds that may help prevent this harmful cell death in immune cells. This study will measure ferroptosis markers in blood samples from lupus patients and test whether the selenium compounds can reduce it.
Lupus damages multiple organs by causing immune cells to become overactive and inflamed. Recent research suggests that ferroptosis — a specific type of cell death triggered by iron — may be driving this inflammation. If the new treatment can block ferroptosis, it could offer a completely new way to help lupus patients.
You likely qualify if…
You likely don't qualify if…
You would visit the research center to have blood samples taken. These samples will be analyzed to measure ferroptosis markers and test how the selenium compound affects your immune cells. The study also includes a comparison group of people with other inflammatory diseases (rheumatoid arthritis or inflammatory bowel disease) to help researchers understand what is unique about lupus.
AI-generated summary from trial data · Jun 14, 2026 · Not medical advice
France
Sponsor
University Hospital, Bordeaux
Enrollment target
~120 participants
Started
April 2026
Primary completion
April 2029
Age range
18 Years and older
Last updated on clinicaltrials.gov in May 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Christophe RICHEZ, Prof
University Hospital, Bordeaux
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.